Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide, Decitabine, and ICIs in R/R NHL and Advanced Solid Tumors
NCT05320640Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Mar 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tucidinostat in non-Hodgkin lymphoma (NHL) and solid tumor, sponsored by Chinese PLA General Hospital. Primary endpoint: Objective Response Rate at 3 years. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
non-Hodgkin lymphoma (NHL)solid tumor
Beyond the preview
Go deeper on NCT05320640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05320640.